ILEU18153 / PTC299 in R / R Acute Leukemias / Michael Becker
Research Question:
What is the safety, pharmacokinetics (PK) profiles, and preliminary evidence of antitumor
activity of PTC299 and the metabolite, O-desmethyl PTC299, in participants with relapsed/refractory
acute myeloid leukemia (AML) who have exhausted standard available therapies known
to provide clinical benefit?
Basic Study Information
Purpose:
This is an open-label, non-randomized, Phase 1b study to evaluate the safety, pharmacokinetics
(PK) profiles, and preliminary evidence of antitumor activity of PTC299 and the metabolite,
O-desmethyl PTC299, in participants with relapsed/refractory acute myeloid leukemia
(AML) who have exhausted standard available therapies known to provide clinical benefit.
The study is designed as a series of cohort-based dose escalations. For each cohort,
a minimum of 3 evaluable participants with PK and safety data will be assessed. Additional
participants will be recruited if additional PK data are needed to assess mean exposure
based on the observed variability.
Location: University of Rochester Medical Center
Study Reference #: ILEU18153
Lead Researcher (Principal Investigator)
Lead Researcher:
Michael Becker, MD
Study Contact Information
Study Coordinator: Jessica Mackowiak
Email: jessica_ellis@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search